Melengestrol Acetate

Melengestrol Acetate

SCHEMBL15079259

C=C1CC2C3C=C(C)C4=CC(=O)CC[C@]4(C)C3CC[C@]2(C)[C@@]1(OC(C)=O)C(C)=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 1.00
MEN1 O00255 2/20 1.00
KMT2A Q03164 2/20 1.00
TDP1 Q9NUW8 1/20 1.00
PGR P06401 5/20 0.69
AR P10275 5/20 0.69
SMN1; SMN2 Q16637 4/20 0.69
NR3C1 P04150 4/20 0.69
CYP3A4 P08684 4/20 0.69
NPSR1 Q6W5P4 3/20 0.69
CYP2C9 P11712 2/20 0.69
HIF1A Q16665 2/20 0.69
MAPK1 P28482 2/20 0.69
ABCB11 O95342 2/20 0.69
POLB P06746 1/20 0.69
CHRM1 P11229 3/20 0.63
ALDH1A1 P00352 2/20 0.55
CHRM2 P08172 2/20 0.55
USP2 O75604 2/20 0.55
ADORA3 P0DMS8 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Melengestrol Acetate SCHEMBL16389279 1.00 LMNA (1.00) LMNAMEN1KMT2ATDP1PGR
Melengestrol Acetate SCHEMBL13778228 1.00 LMNA (1.00) LMNAMEN1KMT2ATDP1PGR
Melengestrol Acetate SCHEMBL10867312 1.00 LMNA (1.00) LMNAMEN1KMT2ATDP1PGR
Melengestrol Acetate SCHEMBL4520 1.00 LMNA (1.00) LMNAMEN1KMT2ATDP1PGR
Melengestrol Acetate SCHEMBL31477812 0.95 LMNA (0.91) LMNAMEN1KMT2ATDP1PGR
SCHEMBL30152035 0.90 LMNA (0.81) LMNAMEN1KMT2ATDP1PGR
SCHEMBL30291851 0.90 LMNA (0.81) LMNAMEN1KMT2ATDP1PGR
SCHEMBL8859712 0.88 LMNA (0.78) LMNAMEN1KMT2ATDP1PGR
SCHEMBL9992871 0.87 LMNA (0.77) LMNAMEN1KMT2ATDP1PGR
SCHEMBL8859672 0.87 LMNA (0.77) LMNAMEN1KMT2ATDP1PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9296780-B2 Process for alkynylating 16-substituted-17-keto steroids CRYSTAL PHARMA, S.A.U. (ES) 2016-03-29 US disclosed
EP-2794632-B1 PROCESS FOR ALKYNYLATING 16-SUBSTITUTED-17-KETO STEROIDS CRYSTAL PHARMA SAU (ES) 2016-03-16 EP disclosed
US-20150005518-A1 PROCESS FOR ALKYNYLATING 16-SUBSTITUTED-17-KETO STEROIDS CRYSTAL PHARMA, S.A.U. (ES) 2015-01-01 US disclosed
WO-2013092668-A1 PROCESS FOR ALKYNYLATING 16-SUBSTITUTED-17-KETO STEROIDS CRYSTAL PHARMA, S.A.U. (ES) 2013-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150005518-A1 PROCESS FOR ALKYNYLATING 16-SUBSTITUTED-17-KETO STEROIDS HSD17B7, NR3C2, CYP17A1 LMNA 553/4885MEN1 196/4885KMT2A 268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.